<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03530306</url>
  </required_header>
  <id_info>
    <org_study_id>Neuromoddevices TENT-A2</org_study_id>
    <nct_id>NCT03530306</nct_id>
  </id_info>
  <brief_title>Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2</brief_title>
  <acronym>TENT-A2</acronym>
  <official_title>Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2 (TENT-A2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuromod Devices Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuromod Devices Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a four arm, patient subtyping and parameter optimisation study for a neuromodulation&#xD;
      treatment for tinnitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with chronic tinnitus will be provided with a CE marked neuromodulation device.&#xD;
      Participants are randomized to one of four different treatment arms. The treatment period is&#xD;
      intended for 12 weeks of use. Based on the clinical investigation plan, participants are&#xD;
      informed that their stimulation settings can change between the first and second halves of&#xD;
      the treatment period and that the differences may be perceptually noticeable. Differences in&#xD;
      tinnitus severity scores will be compared between and within treatment arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Actual">July 18, 2019</completion_date>
  <primary_completion_date type="Actual">October 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tinnitus Handicap Inventory (THI)</measure>
    <time_frame>Between-arm and within-arm changes in THI after 6 weeks of treatment</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Tinnitus Handicap Inventory (THI)</measure>
    <time_frame>Between-arm and within-arm changes in THI after 12 weeks of treatment</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>PS1-PS4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PS6-PS10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PS7-PS4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PS9-PS6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PS1-PS4</intervention_name>
    <description>Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.</description>
    <arm_group_label>PS1-PS4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PS6-PS10</intervention_name>
    <description>Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.</description>
    <arm_group_label>PS6-PS10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PS7-PS4</intervention_name>
    <description>Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.</description>
    <arm_group_label>PS7-PS4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PS9-PS6</intervention_name>
    <description>Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.</description>
    <arm_group_label>PS9-PS6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 70 years of age&#xD;
&#xD;
          -  Ability to read and understand English&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Willing to commit to the full duration of the study&#xD;
&#xD;
          -  Baseline Tinnitus Handicap Inventory (THI) score of &gt;= 38 points&#xD;
&#xD;
          -  Subjective tinnitus of 3 months to 10 years&#xD;
&#xD;
          -  Maximum AC pure-tone audiometry hearing loss of 80 dB HL in any test frequency in the&#xD;
             set {2,3,4,6,8}kHz or 40 dB HL in the set {250,500,1000}Hz either unilaterally or&#xD;
             bilaterally&#xD;
&#xD;
          -  Baseline Minimum Masking Level (MML) of 20 to 80 dB HL&#xD;
&#xD;
          -  Tonal tinnitus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with objective tinnitus&#xD;
&#xD;
          -  Commenced usage of hearing aid within the last 90 days&#xD;
&#xD;
          -  Cases where pulsatility is the dominant feature of tinnitus&#xD;
&#xD;
          -  Patients whose tinnitus cannot be masked during Minimum Masking Level (MML) assessment&#xD;
&#xD;
          -  Meniere's disease&#xD;
&#xD;
          -  Significantly severe Loudness Discomfort Level (LDL, less than 30 dB SL)&#xD;
&#xD;
          -  Depression or neuro-psychological condition, previously diagnosed or identified from&#xD;
             the State-Trait Anxiety Inventory (STAI) with score greater than 120&#xD;
&#xD;
          -  Diagnosed with somatic tinnitus resulting from head or neck injury&#xD;
&#xD;
          -  Temporomandibular Joint Disorder (TMJ)&#xD;
&#xD;
          -  Current or previous involvement in medico-legal cases&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Oral piercings&#xD;
&#xD;
          -  Neurological condition that may lead to loss of consciousness (e.g. epilepsy) or is&#xD;
             considered to be the dominant feature of the tinnitus, as assessed by audiologist or&#xD;
             ENT consultant&#xD;
&#xD;
          -  Severe cognitive impairment based on Mini Mental State Examination (MMSE, less than&#xD;
             20)&#xD;
&#xD;
          -  Patient with a pacemaker or other electro-active implanted device&#xD;
&#xD;
          -  Have used Neuromod Devices products in the past&#xD;
&#xD;
          -  Participants currently prescribed drugs for a central nervous system pathology, i.e.&#xD;
             epilepsy, Multiple Sclerosis (MS), Parkinson's, bi-polar disorder&#xD;
&#xD;
          -  The site Principal Investigator does not deem the candidate to be suitable for the&#xD;
             study for other reasons not listed above&#xD;
&#xD;
          -  Self-reporting episodes of auditory hallucinations&#xD;
&#xD;
          -  Abnormal Otoscopy as assessed by the Audiologist, including active Otitis Media,&#xD;
             perforation and hearing loss that is identified as completely conductive&#xD;
&#xD;
          -  Abnormal Tympanometry as assessed by the Audiologist&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mr. Brendan Conlon</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. James's Hospital, Dublin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. James's Wellness Trust Clinical Research Facility</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <reference>
    <citation>Conlon B, Hamilton C, Hughes S, Meade E, Hall DA, Vanneste S, Langguth B, Lim HH. Noninvasive Bimodal Neuromodulation for the Treatment of Tinnitus: Protocol for a Second Large-Scale Double-Blind Randomized Clinical Trial to Optimize Stimulation Parameters. JMIR Res Protoc. 2019 Sep 27;8(9):e13176. doi: 10.2196/13176.</citation>
    <PMID>31573942</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

